Company profile
eFFECTOR Therapeutics, Inc.
OTC: EFTR · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 38GM —SS 20
v0.1 · 25/100 weight · pillars only
↑ filing timeliness, Altman-Z · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$162.0k
Rev growth YoY (TTM)
-91.9%
Net income (FY)
-$35.8M
Employees
14
as of 2026-08-30
Market cap
$1.4k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$35.8M-$35.8M2023
Operating income-$33.8M-$33.8M2023
Total assets$20.5M$20.5M2023
Liabilities$26.3M$26.3M2023
Equity-$5.8M-$5.8M2023
Revenue trend
FY2021 – FY2023 · USD
FY21
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2021
By product
Grant Revenue100%
Collaboration Revenue0%
By geography
Not disclosed.
The read
What is eFFECTOR Therapeutics, Inc.’s revenue?
eFFECTOR Therapeutics, Inc. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Tengion, Inc.——Claritas Pharmaceuticals, Inc.——Sienna Biopharmaceuticals, Inc.——Global Hemp Group Inc.——OncoVista Innovative Therapies, Inc.——Regnum Corp.——Neighbors
San Diego →Key facts
CEOCraig R. Jalbert
SectorHealthcare
IndustryBiotechnology
HeadquartersSolana Beach, CA
ExchangeOTC: EFTR
Employees14
IPO date2021-03-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.